108Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Hungary
Neuroscience Intelligence
Hungary neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #29 of 50 · Data maturity A · Research score 34.5 · Data confidence 100.0 / 100 · Snapshot 2026-10-29 06:18 UTC.
24Recruiting trials
31Publications
31Institutions
Executive interpretation
Hungary ranks #29 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. Clinical metrics and NCT evidence use only records classified as in_scope or related; out_of_scope records remain preserved outside these analytical counts. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Merck Sharp & Dohme LLC1511 recruiting
Hoffmann-La Roche82 recruiting
Boehringer Ingelheim50 recruiting
UCB Pharma40 recruiting
GlaxoSmithKline30 recruiting
H. Lundbeck A/S30 recruiting
UCB Biopharma S.P.R.L.30 recruiting
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.30 recruiting
Eisai Limited30 recruiting
Eisai Inc.20 recruiting
Disease activity
Parkinsons30trials
Epilepsy24trials
Alzheimers9trials
Multiple Sclerosis8trials
Schizophrenia7trials
Autism6trials
Depression4trials
Stroke3trials
Other Neurology3trials
Neuromuscular3trials
Research institutions
Petz Aladár Megyei Oktató KórházOpenAlexlinked institution
Hungarian Academy of SciencesOpenAlexlinked institution
National Institute of Menthal Health, Neurology and Neurosurgery - Nyírő Gyula HospitalOpenAlexlinked institution
Szent János KórházOpenAlexlinked institution
Budapest University of Technology and EconomicsOpenAlexlinked institution
Pázmány Péter Catholic UniversityOpenAlexlinked institution
HUN-REN Research Centre for Natural SciencesOpenAlexlinked institution
Szent Imre Egyetemi OktatókórházOpenAlexlinked institution
Institute of Molecular Life SciencesOpenAlexlinked institution
Heim Pál Országos Gyermekgyógyászati IntézetOpenAlexlinked institution
Clinical evidence trail
NCT07424404A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and AdolescentsRECRUITING
NCT07216703A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)RECRUITING
NCT06966700A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)RECRUITING
NCT06952504A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)RECRUITING
NCT06887192A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisRECRUITING
NCT06798896RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset SeizuresRECRUITING
NCT06788912Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)RECRUITING
NCT06780085A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)RECRUITING
NCT06463587Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)RECRUITING
NCT06298552A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia GravisACTIVE_NOT_RECRUITING
NCT06180278Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)ACTIVE_NOT_RECRUITING
Research evidence trail
PUBMEDThe salient role of childhood neglect in single and multiple suicide attempts among adult psychiatric inpatients.2026-12-01
PUBMEDSubjective experiences of catatonia in acute psychiatric inpatients: An exploratory study.2026-11-01
PUBMEDEffects of Exercise Training on the Metabolic Cost of Walking in Health and Disease: A Systematic Review and Meta-analysis.2026-10-14
PUBMEDPreoperative White Matter Disease Severity Predicts Intraoperative Cerebral Desaturation During Carotid Endarterectomy.2026-10-03
PUBMEDEarly-Life Feeding Behavior and Sensory Processing in Autism Spectrum Disorder: A Systematic Review and Meta-Analysis.2026-10-03
PUBMEDThe diagnostic order of migraine-depression comorbidity associates with physical, mental, and social disability.2026-10-01
PUBMEDPre-Treatment Levels of Inflammatory Biomarkers as Predictors of Reperfusion Outcomes in Acute Ischemic Stroke: A Systematic Review and Meta-analysis.2026-10-01
PUBMEDEEG spectral power across rest, body scan, and task conditions in Autism and Schizophrenia.2026-10-01
PUBMEDFeasibility and Pilot Validation of the ADHD Child Evaluation (ACEv.2) Clinical Interview.2026-09-06
PUBMEDEstablishment of a novel human nervous system tissue bank: University of Debrecen tissue bank-introduction and retrospective data analysis.2026-09-02
PUBMEDRe-Evaluating the Role of Statistical Learning: Domain-General Predictors of Language in Typical and Atypical Development.2026-09-01
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. Latest collection in this report: 2026-10-24 04:18 UTC. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.